Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Kidney Diseases

Kidney Diseases

Subtypes of Kidney Diseases

Chronic Kidney Disease 134 Nephrotic Syndrome 11 Renal disease 6 Cardiovascular-Kidney-Metabolic Syndrome 5 Renal Stones 4 Hepatorenal Syndrome 3 Minimal Change Disease 3 Nephrolithiasis 3 Steroid-Sensitive Nephrotic Syndrome 3 Contrast-Induced Acute Kidney Injury 2 Obesity-related kidney disease 2 Renal Calculi 2 Sepsis-associated acute kidney injury 2 AL lambda-type amyloid nephropathy 1 Anemia due to Chronic Kidney Disease 1 Autosomal dominant polycystic kidney disease 1 Chemotherapy-related renal injury 1 Chronic Kidney Disease of unknown cause (CKDu) 1 Chronic Kidney Disease Stage 5 1 Continuous renal replacement therapy 1 Contrast-associated Acute Kidney Injury 1 Dent Disease 1 Frequently relapsing nephrotic syndrome 1 Glomerular disease 1 Glomerular filtration rate decline 1 Glomerular injuries 1 Infection-related renal calculi 1 IRIS stage 2 chronic kidney disease 1 Kidney Allograft Rejection 1 Kidney Transplant Dysfunction 1 Kidney transplant recipients 1 Nephropathy 1 Rapid Kidney Function Decline 1 Reduced estimated glomerular filtration rate 1 Renal Artery Occlusion 1 Renal dysfunction 1 Renal failure 1 Renal fibrosis 1 Renal Function 1 Renal impairment 1 Renal inflammation 1 Renal insufficiency 1 Renal involvement 1 Renal ischemia-reperfusion injury 1 Steroid-dependent nephrotic syndrome 1 Steroid-dependent or frequent relapsing nephrotic syndrome 1 Cisplatin-induced acute kidney injury 0 Glomerular injury 0 Uric acid nephropathy 0

184 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Kidney Diseases

26 trials tracked for Kidney Diseases: 8 in phase 3 or 4 and 1 with published results. The most-cited published study has 52 citations.

26Trials tracked
8Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 4 Phase 3 4 Phase 2 7 Phase 1 1 Other / NA 10
  1. Phase 4 CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation Completed · 52 cited
  2. Phase 4 A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment Completed
  3. Phase 4 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Completed
  4. Phase 4 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed
  5. Phase 3 Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives Completed
  6. Phase 3 Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring Completed
Show 20 more trials
  1. Phase 3 Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients Completed
  2. Phase 3 Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection Completed
  3. Phase 2 Study of ISA247 (Voclosporin) in De Novo Renal Transplantation Completed
  4. Phase 2 A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 Completed
  5. Phase 2 Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation Completed
  6. Phase 2 Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation Completed
  7. Phase 2 Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients Completed
  8. Phase 2 Toradol to Reduce Ureteroscopic Symptoms Trial Completed
  9. Phase 2 Ixazomib for Desensitization Completed
  10. Phase 1 PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers Completed
  11. N/A Testosterone Replacement Therapy in Advanced Chronic Kidney Disease Completed
  12. N/A MoveStrong at Home: A Feasibility Study of a Model for Remote Delivery of Functional Strength and Balance Training Combined With Nutrition Education for Older Pre-frail Adults. Completed
  13. N/A Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT) Completed
  14. N/A Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae Completed
  15. N/A Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease Completed
  16. N/A Look AHEAD: Action for Health in Diabetes Completed
  17. N/A Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi) Completed
  18. N/A Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation Completed
  19. N/A Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease Completed
  20. N/A Functional Exercise and Nutrition Education Program for Older Adults Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Kidney Diseases: current evidence & treatments

Multiple studies address diagnostic and prognostic markers in kidney diseases. Cystatin C demonstrates good diagnostic performance for early detection of sepsis-associated acute kidney injury (SA-AKI) with an AUC of 0.88, sensitivity 0.81, and specificity 0.82 1. In diabetic kidney disease (DKD), prediction models for progression to end-stage renal disease show pooled AUCs of 0.896 in training and 0.863 in validation sets 24. Fibroblast growth factor 23 (FGF23) levels are markedly elevated in DKD patients compared to controls (SMD 1.144) 25. Additionally, leukocyte telomere length is shorter in chronic kidney disease (CKD) patients and correlates positively with eGFR 11. Shared genetic loci between pediatric steroid-sensitive nephrotic syndrome and IgA nephropathy have been identified via meta-analysis 13.

Therapeutic interventions show varied benefits. Semaglutide reduces the risk of kidney decline or death in type 2 diabetes and CKD 3. In kidney transplant recipients, steroid avoidance may reduce all-cause death and post-transplant diabetes but increases rejection risk 6. For kidney stones, endoscopic combined intrarenal surgery (ECIRS) triples stone-free odds compared to percutaneous nephrolithotomy (PCNL) for large stones 10, while fluoroless ultrasound-guided techniques lower complications in PCNL with equivalent stone-free rates 9. Jinlida Granule reduces serum creatinine and HbA1c in DKD patients 5. Nutritional vitamin D supplementation in hemodialysis patients reduces C-reactive protein and improves albumin 17. Cerivastatin is most effective for total cholesterol reduction, and simvastatin for LDL-C in DKD with hyperlipidemia 16.

Several studies highlight risk factors and complications. Systemic lupus erythematosus (SLE) patients have a 2- to 3-fold higher risk of intracerebral hemorrhage 2. Prenatal NSAID exposure is associated with increased kidney disease risk in children (aOR 2.40) 23. Gut microbiota dysbiosis is linked to sepsis-associated AKI 4 and CKD complications via the microbiota-gut-kidney axis [7,14]. Complement activation is a convergent mechanism in AKI 22. Exosomes show promise as biomarkers and therapeutic vectors in diabetic complications 15. Education and behavior interventions reduce caregiver burden in CKD 12. Kidney transplantation reduces left-ventricular mass index by 22 g/m² in end-stage kidney disease 8.

Latest findings

AI-generated synthesis of 21 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Nephrology Phase III
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…
CT.gov Mar 30, 2026
Chinese CKD Stage 5 HD patients report ~13 symptoms; symptom distress negatively correlates with QoL
Psychiatry
Chinese CKD Stage 5 HD patients report ~13 symptoms; symptom distress negatively correlates with QoL What's the biggest struggle for people on dialysis? It's not just physical symptoms — it's worry and sleepless nights
A multi-center cross-sectional study of Chinese CKD Stage 5 patients on hemodialysis found patients reported an average of 13 symptoms, with…
People on dialysis in China face severe worry, sexual problems, and sleepless nights, with more symptoms directly lowering their quality of …
Frontiers Mar 30, 2026
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients
Nephrology Phase II
Phase 2 Study Evaluates Abatacept for Kidney Transplant Recipients Could a new biomarker improve kidney transplant outcomes for patients?
A Phase 2 study is recruiting 800 kidney transplant recipients to assess HLA-DR/DQ mMM scores as prognostic biomarkers.
A new kidney transplant biomarker could predict complications, while a follow-up trial tests if switching to abatacept improves function and…
CT.gov Mar 28, 2026
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Nephrology Phase II
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.
CT.gov Mar 27, 2026